GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck & Co Inc (NYSE:MRK) » Definitions » Cash Conversion Cycle
中文

Merck (MRK) Cash Conversion Cycle

: 123.68 (As of Dec. 2023)
View and export this data going back to 1949. Start your Free Trial

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Merck's Days Sales Outstanding for the three months ended in Dec. 2023 was 64.69.
Merck's Days Inventory for the three months ended in Dec. 2023 was 145.66.
Merck's Days Payable for the three months ended in Dec. 2023 was 86.67.
Therefore, Merck's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2023 was 123.68.


Merck Cash Conversion Cycle Historical Data

The historical data trend for Merck's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 130.86 106.16 94.52 88.86 106.32

Merck Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 108.19 107.07 118.04 115.91 123.68

Competitive Comparison

For the Drug Manufacturers - General subindustry, Merck's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck Cash Conversion Cycle Distribution

For the Drug Manufacturers industry and Healthcare sector, Merck's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Merck's Cash Conversion Cycle falls into.



Merck Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Merck's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=60.11+138.85-92.64
=106.32

Merck's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=64.69+145.66-86.67
=123.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Merck  (NYSE:MRK) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Merck Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Merck's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Merck (MRK) Business Description

Address
126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Executives
Johannes Jacobus Oosthuizen officer: SVP, U.S. Market 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Richard R. Deluca officer: EVP&Pres, Merck Animal Heallth 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Steven Mizell officer: EVP,Human Resources 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Joseph Romanelli officer: President, Human Health Int?l 126 EAST LINCOLN AVENUE, RAHWAY NJ 07065
Rita A Karachun officer: Sr. VP Fince-Global Controller 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Jennifer Zachary officer: EVP, General Counsel 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
David Michael Williams officer: EVP,Chief Info&Digital Officer MERCK & CO., INC., 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Robert M Davis officer: Evp, Global Svcs & CFO 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Sanat Chattopadhyay officer: Exe V-P & Pres. MMD 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Kenneth C Frazier officer: Chairman, President & CEO 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Chirfi Guindo officer: Chief Marketing Officer C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Baker Douglas M Jr director 370 WBASHA ST NORTH, ST PAUL MN 55102
Arpa Garay officer: SVP Human Health Global Mktg. 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Caroline Litchfield officer: EVP & CFO 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Julie L. Gerberding officer: EVP Strat Comm, GI Pub Policy 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033

Merck (MRK) Headlines

From GuruFocus

Q3 2022 Merck & Co Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc at Citi BioPharma Conference Transcript

By GuruFocus Research 01-23-2024

Q2 2023 Merck & Co Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc Investor Event at ASCO 2023 Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc To Host ESMO Call (Virtual) Transcript

By GuruFocus Research 01-23-2024